GlassScriptPhysician profile
Karina Patel
NPI 1154006203
$15,559.68
in general payments reported to CMS, 2019-2025
19 companies · $9,295 in 2025
The $9,295 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,138 · 2024: $5,127 · 2025: $9,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,779 · Travel and Lodging: $2,093 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,558.43 |
| Consulting Fee | $2,779.27 |
| Travel and Lodging | $2,093.48 |
| Education | $128.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $4,162.22 | 2023-2025 | Xeomin, Inbrija |
| Abbvie INC. | $2,785.10 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $1,875.10 | 2023-2025 | Rytary, Crexont |
| Medtronic, INC. | $1,612.31 | 2023-2025 | Percept PC Brainsense |
| Abbott Laboratories | $1,147.99 | 2023-2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $810.21 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $636.48 | 2024-2025 | Ingrezza |
| Boston Scientific Corporation | $618.95 | 2024-2025 | Vercise |
| Acadia Pharmaceuticals INC | $609.41 | 2023-2025 | Nuplazid |
| Mdd US Operations, LLC | $321.76 | 2023-2025 | Gocovri, Gocovri |
| Kyowa Kirin, INC. | $274.37 | 2023-2024 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $231.27 | 2024-2025 | Dysport |
| Cala Health, INC. | $139.74 | 2025 | Cala Kiq |
| Biogen, INC. | $78.00 | 2025 | Skyclarys |
| Ge Healthcare | $69.66 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $61.78 | 2024 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $47.93 | 2023-2024 | Nuedexta, Rexulti |
| Supernus Pharmaceuticals, INC. | $43.20 | 2025 | Qelbree |
| Azurity Pharmaceuticals, INC. | $34.20 | 2024-2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.